<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587652</url>
  </required_header>
  <id_info>
    <org_study_id>2114-02</org_study_id>
    <secondary_id>IRUSEOMO164</secondary_id>
    <nct_id>NCT00587652</nct_id>
  </id_info>
  <brief_title>Methylene Blue Chromoendoscopy in Barrett's Esophagus</brief_title>
  <official_title>A Prospective Trial of Methylene Blue Chromoendoscopy in Barrett's Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to:

      Determine if a temporary dye applied to the esophagus identifies areas of dysplasia
      (pre-cancer). Determine if certain dye patterns indicate specific grades of dysplasia.
      Determine if overall endoscopy costs can be reduced with this dye technique. Determine if the
      dye could allow fewer biopsies to be obtained in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although methylene blue has been used effectively to identify areas of SIM in several
      studies, its superiority in identifying dysplasia in the setting of Barrett's esophagus has
      been inconclusive. In all studies to date dysplastic yield was equivalent or better than
      protocol techniques while requiring fewer biopsies. Variations in study design, staining
      technique and inexperience in staining interpretation are some of the reasons. Our goal is to
      build on the techniques that have been shown to be effective, standardize them for the
      purposes of our study, and to objectively evaluate if MB directed biopsies are useful in
      screening Barrett's patients for dysplasia. At the time of EGD when length of Barrett's is
      determined, patients will be stratified into either intermediate (2-4cm) or long segment
      (&gt;4cm) Barrett's. Short segment Barrett's esophagus patients will not be considered, as MB
      techniques have not proved beneficial in dysplasia detection as previously described 7.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Any dysplasia or adenocarcinoma detected over all biopsies using each method.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The association between staining patterns and histologic grade of the biopsies obtained using methylene blue will be assessed.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Intermediate Segment Barrett's (2-4cm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Long segment Barrett's (&gt;4 cm)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting for surveillance upper endoscopy to assess Barrett's esophagus.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of Barrett's with or without dysplasia

          -  Able to give consent

        Exclusion Criteria:

          -  Pregnancy or women of child-bearing potential

          -  Active esophagitis

          -  Esophageal varices

          -  Esophageal cancer (history of or current)

          -  Hypersensitivity to methylene blue

          -  Severe renal impairment (creatinine&gt;2.0)

          -  Known glucose-6-phosphate dehydrogenase (G-6-PD) deficiency

          -  Symptomatic coronary artery disease

          -  Coagulopathy (INR&gt;/=1.5)

          -  Thrombocytopenia &lt;/= 20K/ul

          -  Previous esophageal ablative therapy (EMR,PDT, APC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher G Gostout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic, Rochester, MN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Rajan E, Burgart LJ, Gostout CJ. Endoscopic and histologic diagnosis of Barrett esophagus. Mayo Clin Proc. 2001 Feb;76(2):217-25.</citation>
    <PMID>11213314</PMID>
  </reference>
  <reference>
    <citation>Gopal DV. Another look at Barrett's esophagus. Current thinking on screening and surveillance strategies. Postgrad Med. 2001 Sep;110(3):57-8, 61-2, 65-8. Review.</citation>
    <PMID>11570206</PMID>
  </reference>
  <reference>
    <citation>Canto MI, Setrakian S, Petras RE, Blades E, Chak A, Sivak MV Jr. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc. 1996 Jul;44(1):1-7.</citation>
    <PMID>8836709</PMID>
  </reference>
  <reference>
    <citation>Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol. 1997 Mar;92(3):407-13.</citation>
    <PMID>9068459</PMID>
  </reference>
  <reference>
    <citation>Fennerty MB, Sampliner RE, McGee DL, Hixson LJ, Garewal HS. Intestinal metaplasia of the stomach: identification by a selective mucosal staining technique. Gastrointest Endosc. 1992 Nov-Dec;38(6):696-8.</citation>
    <PMID>1282115</PMID>
  </reference>
  <reference>
    <citation>Canto MI. Vital staining and Barrett's esophagus. Gastrointest Endosc. 1999 Mar;49(3 Pt 2):S12-6.</citation>
    <PMID>10049441</PMID>
  </reference>
  <reference>
    <citation>Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, Sivak MV Jr. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc. 2000 May;51(5):560-8.</citation>
    <PMID>10805842</PMID>
  </reference>
  <reference>
    <citation>Kiesslich R, Hahn M, Herrmann G, Jung M. Screening for specialized columnar epithelium with methylene blue: chromoendoscopy in patients with Barrett's esophagus and a normal control group. Gastrointest Endosc. 2001 Jan;53(1):47-52.</citation>
    <PMID>11154488</PMID>
  </reference>
  <reference>
    <citation>Sharma P, Topalovski M, Mayo MS, Weston AP. Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus. Gastrointest Endosc. 2001 Sep;54(3):289-93.</citation>
    <PMID>11522967</PMID>
  </reference>
  <reference>
    <citation>Canto MI, Yoshida T, Gossner L. Chromoscopy of intestinal metaplasia in Barrett's esophagus. Endoscopy. 2002 Apr;34(4):330-6. Review.</citation>
    <PMID>11932792</PMID>
  </reference>
  <reference>
    <citation>Canto MI. Methylene blue chromoendoscopy for Barrett's esophagus: coming soon to your GI unit? Gastrointest Endosc. 2001 Sep;54(3):403-9.</citation>
    <PMID>11522995</PMID>
  </reference>
  <reference>
    <citation>Wo JM, Ray MB, Mayfield-Stokes S, Al-Sabbagh G, Gebrail F, Slone SP, Wilson MA. Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a preliminary study. Gastrointest Endosc. 2001 Sep;54(3):294-301.</citation>
    <PMID>11522968</PMID>
  </reference>
  <reference>
    <citation>Canto M, Wu T, Kalloo A. High Magnification Endoscopy with Methylene Blue Chromoendoscopy for Improved Diagnosis of Barrett's Esophagus and Dysplasia. Gastrointestinal Endoscopy 2001;53(5):AB4171.</citation>
  </reference>
  <reference>
    <citation>Sueoka N, Tabuchi M, Nishigaki H, Sakamoto C, Kobayashi M, Sasajima K. Magnification Endoscopy with Vital Dye Staining For Detection Of A Minute Focus of Early Adenocarcinoma In Barrett's Esophagus. Gastrointestinal Endoscopy 2001;53(5):AB4139.</citation>
  </reference>
  <reference>
    <citation>Gangarosa LM, Halter S, Mertz H. Methylene blue staining and endoscopic ultrasound evaluation of Barrett's esophagus with low-grade dysplasia. Dig Dis Sci. 2000 Feb;45(2):225-9.</citation>
    <PMID>10711429</PMID>
  </reference>
  <reference>
    <citation>Breyer H, Maguilnik I, Barros S. Methylene Blue Can Disclose Intestinal Metaplasia In Barrett's Esophagus? Gastrointestinal Endoscopy 2000;51(4):AB3521.</citation>
  </reference>
  <reference>
    <citation>Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001 Apr;32(4):368-78.</citation>
    <PMID>11331953</PMID>
  </reference>
  <reference>
    <citation>Katzka DA, Rustgi AK. Gastroesophageal reflux disease and Barrett's esophagus. Med Clin North Am. 2000 Sep;84(5):1137-61. Review.</citation>
    <PMID>11026922</PMID>
  </reference>
  <reference>
    <citation>Canto MI, Setrakian S, Willis JE, Chak A, Petras RE, Sivak MV. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study. Endoscopy. 2001 May;33(5):391-400.</citation>
    <PMID>11396755</PMID>
  </reference>
  <reference>
    <citation>Hackelsberger A, Günther T, Schultze V, Manes G, Dominguez-Muñoz JE, Roessner A, Malfertheiner P. Intestinal metaplasia at the gastro-oesophageal junction: Helicobacter pylori gastritis or gastro-oesophageal reflux disease? Gut. 1998 Jul;43(1):17-21.</citation>
    <PMID>9771400</PMID>
  </reference>
  <reference>
    <citation>Goldman AI. Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Control Clin Trials. 1987 Dec;8(4):327-37.</citation>
    <PMID>3327653</PMID>
  </reference>
  <reference>
    <citation>Canto MI. Chromoendoscopy and magnifying endoscopy for Barrett's esophagus. Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S12-5. Review.</citation>
    <PMID>16012986</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>January 5, 2010</last_update_submitted>
  <last_update_submitted_qc>January 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christopher J. Gostout MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Barrett Esophagus</keyword>
  <keyword>Methylene blue</keyword>
  <keyword>Chromoendoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

